Dr. Zahoor Ahmad Parry

Clinical Microbiology Division
CSIR - Indian Institute of Integrative Medicine,Canal Road, Jammu – 180001
Email: zahoorap[at]iiim[dot]ac[dot]in

Positions Held  
Position Held Date Organization
Sr. Scientist   2010 - Present CSIR-IIIM


Pharmacokinetics and Pharmacodynamics of antimicrobials in animal models, Use of Pharmacokinetic/Pharmacodynamic Robert to study human drug exposures and their effects, Drug-drug interactions, Drug toxicity, Development and characterization of Drug delivery systems, Role of nanotechnology in drug delivery, Development of new drugs as well as new combination regimens, Development and characterization of new in vitro and animal models of human diseases with special reference to tuberculosis. Evaluation of new molecules against drug susceptible, persistent, latent or multi/extensively drug resistant M.tuberculosis. Evaluation of new immuno-therapeutic agents and vaccines against experimental TB. Drug susceptibility testing of natural/synthetic molecules against Gram positive & Gram negative bacteria, and several Fungal Strains.

  • Ahmad,Z.; Tyagi,S.; Eric, L. Nuermberger and Jacques H Grosset. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med. 2013; in press.

  • Ahmad,Z.; Fraig, M. M.; Pinn,M.; Tyagi,S.;  Eric ,L. ;Jacques Grosset,N.; Petros ,C. Karakousis. Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother. 2011; 66(7):1560-1566.

  • Pandey ,R.; Ahmad,Z .;. Nanomedicine and tuberculosis: facts, flaws and future.  Nanomedicine. Review article. 2011; 7(3):259-272.

  • Ahmad,Z .;. Peloquin ,C.; Minkowski, A.; Williams, K.; Khisimuzi, E.; Mdluli, Grosset J. H .; Eric ,L. Nuermberger. Activity of the fluoroquinolone DC-159a in the initial and continuation phase treatment of murine tuberculosis. Antimicrob Agents Chemother. 2011; 55(4):1781-1783.

  • Zhang,Ming .; Li,Si-Yang.; Rosenthal, I. M. ; Almeida,D.;Ahmad, Z.; Converse,P.; Peloquin,C.; Eric, L. Nuermberger and Jacques H. Grosset. Treatment of tuberculosis with rifamycin-containing regimens in immune deficient mice. Am J Respir Crit Care Med. 2011; 183(9):1254. 

  • Almeida,D.; Converse,P.; Ahmad,Z.; Dooley, K. E. ;Eric, L. Nuermberger and Jacques H. Grosset. Activities of rifampin, rifapentine and clarithromycin, against Mycobacterium ulcerans disease in mice. PLOS Neglected Tropical Diseases. 2011; 5(1):e933.

  • Ahmad,Z.; Peloquin,C. A.;Singh, R.P. ; Derendorf,H.; Tyagi, S..;Ginsberg,A.; Grosset , J.H.; Eric ,. Nuermberger. PA-824 exhibits time-dependent activity in a murine model of tuberculosis.  Antimicrob Agents Chemother. 2011; 55(1):239-245.

  • Ahmad,Z.; Klinkenberg,L. G.; Pinn,M.; Fraig,M.M.; Peloquin,Charles A.; Eric, L. Nuermberger, Jacques H. Grosset and Petros C. Karakousis. Biphasic Kill Curve of Isoniazid Reveals the Presence of Drug-Tolerant, Not Drug-Resistant, Mycobacterium tuberculosis in the Guinea Pig. J Infect Dis. 2009; 200(7):1136-1143.

  • Ahmad,Z.;Sharma, S.; Khuller,G.K. . Chemotherapeutic evaluation of alginate nanoparticle encapsulated azole antifungal and anti-tubercular drugs against murine tuberculosis. Nanomedicine. 2007; 3 (3):239-243.

  • Ahmad,Z.;Sharma, S.; Khuller,G.K.; Singh,P.;Faujdar , Jaya .; Katoch,V.M.. Antimycobacterial potential of Econazole against multidrug resistant strains of Mycobacterium tuberculosis. Int J Antimicrob Agents 2006; 28(6):543-544.